Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
- 129 Downloads
The control of chemotherapy-induced nausea and vomiting (CINV) is critical in preventing poor health outcomes and increasing patient quality of life. The objective of this study was to evaluate the impact of the addition of casopitant to dual-combination therapy of dexamethasone and ondansetron on quality of life in patients receiving highly emetogenic chemotherapy (HEC).
In a multicenter, double-blind, randomized, placebo-controlled, add-on trial (N = 810), patients were randomized to intravenous (IV) ondansetron/dexamethasone alone (control) or in combination with either a single 150-mg oral dose of casopitant or 3-day IV/oral casopitant. Quality of life was assessed as impact of nausea and vomiting on daily life using the Functional Living Index Emesis (FLIE) questionnaire. Patients completed the FLIE questionnaire at baseline prior to receiving chemotherapy and after completion of the first cycle of HEC.
Patients in the single oral dose and 3-day IV/oral casopitant groups scored higher mean total FLIE scores (115.7 and 114.0, respectively; p ≤ 0.0332) than patients in the control group (107.5), indicating that casopitant patients experienced less impact from nausea and vomiting on daily life. The overall absolute difference in the proportion of patients reporting CINV with no impact on daily life between the single oral casopitant group and the control group was 13%; the difference between the 3-day IV/oral casopitant group and the control group was 14%.
The addition of casopitant to ondansetron and dexamethasone in patients receiving HEC was significantly more effective in reducing the impact of nausea and vomiting on all daily life activities as assessed by the FLIE compared with ondansetron/dexamethasone dual therapy.
KeywordsCasopitant Highly emetogenic chemotherapy Quality of life Functional Living Index Emesis (FLIE) questionnaire
The authors acknowledge Kim Poinsett-Holmes, PharmD (Poinsett Publications, Inc.), for her editorial assistance with the submitted manuscript. This study was supported by a research grant from GlaxoSmithKline.
- 5.Voliotis DL, Diehl V (1998) Clinical aspects and prognostic factors of nausea and vomiting after chemotherapy. In: DiCato MA (ed) Medical management of cancer treatment induced emesis. Martin Dunitz, Philadelphia, pp 45–54Google Scholar
- 6.Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12:596–600PubMedGoogle Scholar
- 9.Hickock JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytriptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880–2886CrossRefGoogle Scholar
- 10.Hesketh PJ, Gralla RJ, Webb RT, Ueno W, Delprete S, Bachinski ME, Dirlam NL, Stack CB, Silberman SL (1999) Randomized phase II study of the neurokinin I receptor antagonist CJ-11, 974 in the control of cisplatin-induced emesis. J Clin Oncol 1791:338–343Google Scholar
- 12.Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O’Brien M, Schellens JH, Borms M, Verbeke L, Van Aelst F, De Smet M, Carides A, Eldridge K, Gertz BJ (2001) Comparison of L-758, 298, a prodrug for the selective neurokinin-1 antagonist, L-754, 030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37:835–842CrossRefPubMedGoogle Scholar
- 13.Horgan KJ, Eldridge KN, Carides A, Van Belle S, Hesketh PJ (2001) Differential time course of cisplatin induced acute emesis with a 5HT3 antagonist or an NK1 antagonist: rationale for combination therapy. Proc ASCO 20:383a AbstractGoogle Scholar
- 14.Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J (2009) Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Lancet Oncol 10:549–558CrossRefPubMedGoogle Scholar
- 22.National Comprehensive Cancer Network. Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed 1 August 2008